99884-77-2

Upstream product

• 41252-83-9 2-bromo-2-phenylethanol 

Downstream Products

• 118469-70-8 2-(acetyloxy)-3-(hexadecyloxy)propyl-phosphoric acid, 2-bromo-2-phenyl-ethyl ester 

Relevant academic research and scientific papers

SULFUR INHIBITORS OF PHOSPHOLIPASE A-Z

Phospholipase A2 inhibitors having the formula wherein R" is a C2-C20 alkyl group, R1" is a C1-C4 alkyl group, y is an integer from 2 to 10, and J- is a pharmaceutically acceptable anion, are described

Antihypertensive phosphate derivatives

Antihypertensive phosphate derivatives having the following formula are described: STR1 wherein X is selected from one or more of: (a) C1 -C24 branched or straight chain alkyl; (b) C1 -C24 branched or straight chain alkoxy; (c) STR2 wherein n and m are integers from 0 to 25 and the sum of n and m is less than or equal to 25; phenyl; substituted phenyl wherein the substituents are selected from the group consisting of C1 -C20 branched or straight chain alkyl, C1 -C20 branched or straight chain alkoxy, halogen, trifluoromethyl, phenyl, and substituted phenyl, phenoxy; and substituted phenoxy, wherein the substituents are selected from the group consisting of C1 -C20 branched or straight chain alkyl, halogen, trifluoromethyl, phenyl and substituted phenyl; Q is selected from the group consisting of: STR3 wherein R1 is selected from the group consisting of hydrogen, C1 -C4 branched or straight chain alkyl, C1 -C4 branched or straight chain alkoxy and C1 -C4 branched or straight chain alkylamino and wherein R3 is C1 -C4 alkyl, with the proviso that when Q is STR4 then R1 is C1 -C4 branched or straight chain alkyl; T is a bivalent radical selected from the group consisting of --(CHR)p -- and STR5 wherein p is an integer from 1 to 15, the moiety --(CHR)p -- represents an alkylene chain substituted at any position with one or more C1 -C10 alkyl groups or phenyl groups, and the moiety STR6 is bound with the oxygen atom attached directly to the aromatic ring; and Z is STR7 wherein R2 is hydrogen or C1 -C4 branched or straight chain alkyl and q is an interger from 4 to 7; in either the racemic or optically active forms.

Analogues of platelet activating factor. 4. Some modifications of the phosphocholine moiety

Racemic analogues of platelet activating factor (PAF) in which the methylene bridge separating the phosphate and trimethylammonium moieties is altered in length (7a-f) have been prepared. Increasing the length of this bridge results in a progressive decrease in the hypotensive and platelet aggregation responses. Analogues in which the phosphocholine group is substituted with a methyl group (7h and 7i) or a phenyl group (5j) or in which the methylene bridge is replaced with a meta-substituted benzyl group (5k) have been prepared. With respect to both the blood pressure and platelet aggregation responses, 7i and 5k showed little if any changes in potency compared to racemic C16-PAF. While 7h is more potent than 1a with respect to both the hypotensive and platelet aggregation properties, 5j is less potent. Replacement of the phosphate moiety of C18-PAF with a phosphonate group leads to decreased activity in both assays. Analogue 11, in which the phosphocholine group has been replaced with a 4-(trimethylammonio)butoxy group, exhibited no detectable hypotensive or platelet aggregating activity. None of the analogues exhibited a separation of the blood pressure and platelet aggregation activities.